Goldman Sachs Group Analysts Give Roche (ROG) a CHF 325 Price Target
Roche (VTX:ROG) has been given a CHF 325 target price by equities research analysts at Goldman Sachs Group in a note issued to investors on Thursday. The firm presently has a “buy” rating on the healthcare company’s stock. Goldman Sachs Group’s price target would indicate a potential upside of 34.13% from the stock’s current price.
Several other research analysts have also recently commented on ROG. Morgan Stanley set a CHF 260 price target on Roche and gave the stock a “neutral” rating in a research note on Friday, December 1st. UBS set a CHF 260 price target on Roche and gave the stock a “neutral” rating in a research note on Wednesday. Berenberg Bank set a CHF 273 price target on Roche and gave the stock a “buy” rating in a research note on Tuesday, August 15th. J P Morgan Chase & Co reiterated a “buy” rating on shares of Roche in a research note on Monday, October 2nd. Finally, Sanford C. Bernstein set a CHF 262 price target on Roche and gave the stock a “buy” rating in a research note on Friday, December 1st. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of CHF 261.32.
Shares of Roche (VTX ROG) traded down CHF 4.90 on Thursday, hitting CHF 242.30. The company’s stock had a trading volume of 3,290,000 shares, compared to its average volume of 1,690,000. Roche has a 12 month low of CHF 219.10 and a 12 month high of CHF 273.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.